Our Science

Revolutionizing the application of small molecule, bi-specific immunotherapies.

  • Phase I Clinical Trials for EV25 are slated to begin at the end of 2024.

    Clinical Trials

    Modularity in Action

    Our modular platform can be applied to a wide variety of disease states. We are currently developing variants for RSV, as well as other respiratory viruses and non-viral infections.

    Development Pipeline